-
Product Insights
Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D – Drugs In Development, 2022, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape. Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV)...
-
Product Insights
Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome. The NASH drugs in development market research report provides comprehensive information on the...
-
Product Insights
Primary Sclerosing Cholangitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Primary Sclerosing Cholangitis pipeline market research report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis...
-
Product Insights
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation. The Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development market research report provides an overview of the Primary Biliary Cholangitis (Primary...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort. The NAFLD drugs in development market research report provides comprehensive information on the therapeutics under development for the NAFLD, complete...
-
Sector Analysis
Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants. The Pruritus- Drugs in Development research report provides a comprehensive overview on the therapeutics under...
-
Product Insights
Cholestasis Disease – Global Clinical Trials Review, H2 2020
GlobalData's clinical trial report, “Cholestasis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cholestasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cholestasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Global Clinical Trials Review, H2, 2020" provides an overview of Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Biliary Cholangitis (Primary Biliary Cirrhosis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Sector Analysis
United States Diabetes Care Devices Market Outlook to 2025 – Glucose Monitoring and Insulin Delivery
GlobalData’s “United States Diabetes Care Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Diabetes Care Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Glucose Monitoring and Insulin Delivery. The United States Diabetes Care Devices Market report provides key information and data on: • Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments....
-
Product Insights
Primary Sclerosing Cholangitis Disease – Global Clinical Trials Review, H1 2020
GlobalData's clinical trial report, “Primary Sclerosing Cholangitis Global Clinical Trials Review, H1, 2020" provides an overview of Primary Sclerosing Cholangitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Sclerosing Cholangitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...